Adverse events
ADVERSE EVENTS, ADVERSE EVENT, EVENT
Safety was evaluated in the safety population, participants who received at least one dose of neuroEPO plus or placebo. Safety evaluations included monitoring of adverse events, vital signs, physical examinations and clinical laboratory variables. Adverse events were collected from the first administration of study drug until the patient’s final visit in the study and were summarized according to event frequency by treatment assignment. Frequency distributions by treatments were estimated. No safety monitoring of the MRI data was done.